CD19 and acute lymphoblastic leukemia: One patient with B-cell acute lymphoblastic leukemia (B-ALL) has maintained minimal residual disease (MRD)-negative remission for over 14 months after CD19/CD22 bispecific CAR-T cell therapy [71].